Study found that prophylaxis with palivizumab does not represent good value for money based on the current UK incremental cost-effectiveness ratio threshold of £30,000/quality-adjusted life-year when used unselectively in pre-term infants without chronic lung disease (CLD)/congenital heart disease (CHD) or children with CLD or CHD.